CStone braves the HKEX with late-stage plans brewing for newly beefed up I/O pipeline
This May, when CStone bagged $260 million in what it said was the largest Series B funding in the history of the Chinese biopharma industry, CEO Frank Jiang heralded the round as critical for the company’s “current and near-term growth.” It quickly became clear how: Within weeks, the fast-growing Chinese immuno-oncology player sealed licensing deals with two rising US biotech stars, diversifying the molecular targets being addressed by its clinical pipeline, and poached seasoned Goldman Sachs healthcare managing director Richard Yeh to be its new CFO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.